P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION

Hemasphere · 2022 · PMC9429402

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

an apparent trendno p-value reported

Based on the risk-adjusted analysis, we witnessed an apparent trend toward increased OS with FEDR, but the observed differences did not achieve statistical significance (HR [95% CI]: 0.6 [0.3–1.2]; P =0.1466).

also in 709 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.